Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 known ✓ | P23921 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 7/20 | 0.44 |
| ▸ | NPY1R | P25929 | 5/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | OTC | P00480 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL866931 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL29027297 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL940540 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL14840576 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL940539 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| SCHEMBL42488 | 0.98 | NPY4R (0.45) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| SCHEMBL2172217 | 0.98 | NPY4R (0.45) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| SCHEMBL157856 | 0.98 | NPY4R (0.45) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Guanidine SCHEMBL8907224 | 0.97 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| SCHEMBL2236129 | 0.97 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116199836-A | Block polymer material, preparation method and application thereof, and nano drug delivery system | 中山大学附属第七医院(深圳) | 2023-06-02 | — | — | CN | claimed |
| CN-106178988-B | A kind of polyvinylidene fluoride blending film of photosynthesis-carbon dioxide response and preparation method thereof | 台州学院 | 2019-09-24 | — | — | CN | claimed |
| WO-2002098824-A2 | IMPROVEMENTS IN ENZYME STABILITY | UNISEARCH LIMITED (AU) | 2002-12-12 | — | — | WO | claimed |
| CN-115650894-B | Amphoteric calixarene derivative, composite catalyst containing amphoteric calixarene derivative and application of amphoteric calixarene derivative | 北京旭阳科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-117800861-A | Amino acid and derivative ionic liquid thereof, and preparation method and application thereof | 中国药科大学 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-116199836-A | Block polymer material, preparation method and application thereof, and nano drug delivery system | 中山大学附属第七医院(深圳) | 2023-06-02 | — | — | CN | disclosed |
| CN-115650894-A | Amphoteric calixarene derivative, composite catalyst containing amphoteric calixarene derivative and application of composite catalyst | 北京旭阳科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-113265050-B | Degradable high polymer material, self-assembled nano composite and application | 浙江大学 | 2022-08-23 | — | — | CN | disclosed |
| EP-3823530-A1 | SYSTEMS AND METHODS FOR MEASURING LIVER ENZYME LEVELS IN BLOOD | Nova Biomedical Corporation (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-111567541-B | Preparation method and application of nano pesticide for conduction of plant phloem | 华南农业大学 | 2021-05-07 | — | — | CN | disclosed |
| US-20050107305-A1 | Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities | SOCIETE DIAGNOSTICA-STAGO (FR) | 2005-05-19 | — | — | US | disclosed |
| CN-1524087-A | Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities | — | 2004-08-25 | — | — | CN | disclosed |
| WO-2003056001-A1 | MODIFIED ENZYMES AND MODIFICATION PROCESSES | UNISEARCH (AU) | 2003-07-10 | — | — | WO | disclosed |
| WO-1999043345-A1 | AMINO ACID DEGRADING ENZYMES MODULATE CELL DEATH | EISAI CO., LTD. (JP) | 1999-09-02 | — | — | WO | disclosed |
| EP-0506468-B1 | N-substituted 4-phenyl-piperidine opioid-antagonists | LILLY CO ELI (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5270328-A | Peripherally selective piperidine opioid antagonists | ELI LILLY AND COMPANY (US) | 1993-12-14 | — | — | US | disclosed |
| US-5159081-A | INTERMEDIATES OF PERIPHERALLY SELECTIVE N-CARBONYL-3,4,4-TRISUBSTITUTED PIPERIDINE OPIOID ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0506468-A1 | N-substituted 4-phenyl-piperidine opioid-antagonists | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| US-4568725-A | POLYMERS MODIFIED SULFONATE DERIVATIVES AND SULFONATED ARGININE DERIVATIVES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1986-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107305-A1 | Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities | CPA3, CPA4, CPA1 | RRM1 2186/4885NPY4R 412/4885NPY1R 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.